Please ensure Javascript is enabled for purposes of website accessibility

The Smartest Stocks to Buy With $200 Right Now

By Sean Williams - Jul 9, 2021 at 5:51AM

Key Points

  • For investors with a long-term mindset, it's always a good time to put money to work in the stock market.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

You don't need to start with a pile of cash to build wealth on Wall Street.

The stock market offers few guarantees. However, the market has historically been kind to investors who take a long-term approach.

According to data from Crestmont Research, there's never been a rolling 20-year period where the broad-based S&P 500 has delivered a negative return to investors. Put another way, it doesn't matter when you put your money to work in the stock market. As long as you allow your investment thesis to play out over time, you have a very good chance to build wealth on Wall Street.

Another great thing about putting your money to work in equities is that you don't need to be rich to make money. If you have $200 at your disposal, which won't be needed to cover emergencies or pay bills, this is more than enough to buy some of the smartest stocks right now.

Two slightly curled  hundred dollar bills on a white surface.

Image source: Getty Images.


First up on the buy list is pharmaceutical stock AstraZeneca (AZN -0.39%). Although AstraZeneca was a significant laggard for much of the past two decades due to competition and the patent cliff, it's found new life thanks to a number of blockbuster medications and inorganic opportunity.

Whereas most Big Pharma stocks are slow-growing cash cows, AstraZeneca is actually a rapidly growing cash cow with what looks to be a sustainable double-digit sales growth rate through mid-decade. Leading the charge are its blockbuster trio of oncology drugs (Tagrisso, Imfinzi, and Lynparza), as well as next-generation type 2 diabetes treatment Farxiga. The company's cancer-drug trio helped push oncology sales up 20% in the first quarter, while sales of Farxiga rose by 50%. The latter lifted cardiovascular (CV) segment sales higher by 19%, even with revenue declines from other core CV therapies. 

Beyond increased demand and improved pricing power for its key brand-name drugs, AstraZeneca is making a huge acquisition to broaden its portfolio and pump up its cash flow over the next decade. Its pending deal to buy Alexion Pharmaceuticals (ALXN) will bring a top-notch ultra-rare-disease drug developer into the fold. Though it's risky to develop treatments for very small patient pools, the reward is a high list price that insurers don't question and nonexistent competition.

Perhaps the best part of this deal is that AstraZeneca doesn't have to worry about losing sales once Alexion's top-selling drug, Soliris, loses exclusivity. That's because Alexion developed a next-generation replacement therapy, known as Ultomiris, which the U.S. Food and Drug Administration has approved. Since Ultomiris is administered less frequently than Soliris, it represents a clear improvement in patient quality of life and treatment efficacy. This should allow Ultomiris to eventually absorb Soliris's more than $4 billion in annual sales.

After years of underperformance, AstraZeneca is finally the growth company Wall Street always hoped it would be.

Esports gamer pumping fist in the air while holding a smartphone.

Image source: Getty Images.


Another one of the smartest stocks you can buy with $200 right now is esports and gaming company Skillz (SKLZ 7.01%). Though it certainly sports a premium valuation, the growth and partnership potential here should play out favorably for long-term investors.

Whereas most gaming companies choose the road frequently traveled and take on the major game developers, Skillz didn't do that. Instead, it built a platform that allows gamers to compete against each other for cash prizes. In exchange for providing a platform for these competitions to take place, Skillz and the game developer in question get to a keep a cut of the cash prize. It's a lot cheaper and far more successful to develop a gaming medium than it is to develop a game and hope it finds its mark.

Although it's very early, the initial results are incredibly promising. Skillz had 467,000 paying monthly active users as of the end of March. This works out to 17% of the players on its platform. For some context here, Wappier Gaming Apps notes that pay-to-play conversion rates ranged from 1.6% to 2% in 2020. This suggests Skillz has between eight and 10 times higher conversion rates than the industry average. Plus, the company is generating a 95% gross margin on the revenue it's bringing in. 

As I've alluded, there's also serious partnership potential here as a mobile gaming medium. In February, Skillz landed a multiyear agreement with the National Football League (NFL). Football is the undisputed most popular sport in the United States. With this agreement, developers will be able to debut NFL-themed games on the Skillz platform beginning no later than 2022.

For the time being, Skillz will be expanding its headcount and spending aggressively on marketing to build its brand and get gamers and mobile developers interested. That means bigger losses in the near term. But with $1 billion in annual revenue a very real target by 2025, if not sooner, Skillz looks to have all the tools needed to make investors rich.

Businesspeople shaking hands.

Image source: Getty Images.

Bank of America

A final smart stock long-term investors can confidently buy with $200 right now is banking giant Bank of America (BAC 1.68%).

There's no question that banks have enjoyed a monstrous run-up over the past eight months. But this looks like just the beginning. That's because rising inflation and a rebounding U.S. economy are opening the door for the Federal Reserve to act by 2023, if not earlier.

The nation's central bank is responsible for setting the federal funds rate, which is the interest rate at which depository institutions lend reserve balances to other depository institutions. Without getting overly technical, adjustments to the federal funds rate affect interest rates and can affect mortgage rates. When the Fed begins raising rates, bank stocks will receive an immediate boost to their net interest income via variable-rate loans. No bank is more interest-sensitive than Bank of America.

According to the company's first-quarter operating results, a 100-basis-point parallel shift in the interest rate yield curve would produce an estimated $8.3 billion in added net interest income over the next 12 months. While these hikes are more than 12 months away, bond yields have already begun rising, which is a good sign for future bank profits.

What's more, Bank of America has been cutting costs and spending aggressively in all the right places. The push toward digitization is paying off handsomely, with more than 40 million people banking digitally with BofA in the first quarter, up almost 5 million from three years ago. Most importantly, the percentage of sales completed online or via mobile skyrocketed to 49% in first-quarter 2021 from 33% in the year-ago quarter. This shift to online banking is considerably cheaper for Bank of America, and it's allowed the company to close and consolidate some of its branches. 

With the Great Recession now a distant memory, it's time for investors to believe in the long-term growth potential of Bank of America.

Bank of America is an advertising partner of The Ascent, a Motley Fool company. Sean Williams owns shares of Bank of America and Skillz Inc. The Motley Fool owns shares of and recommends Skillz Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bank of America Corporation Stock Quote
Bank of America Corporation
$33.96 (1.68%) $0.56
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.03 (-0.39%) $0.26
Skillz Inc. Stock Quote
Skillz Inc.
$1.68 (7.01%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.